Trilaciclib is a CDK4/6 Inhibitor for Kinds of Cancer Research
CDK4/6 is a Ser/Thr protein kinase that is active only in the G1-S phase. It is controlled by the regulatory subunit D-type cyclin and the CDK inhibitor p16INK4a; involved in the…
CDK4/6 is a Ser/Thr protein kinase that is active only in the G1-S phase. It is controlled by the regulatory subunit D-type cyclin and the CDK inhibitor p16INK4a; involved in the…
Pyruvate kinase has four different tissue-specific isozymes in animals, PKL, PKR, PKM1, and PKM2. As reported, PKM2 is highly expressed in many types of human cancers. Besides, the dimer PKM2…
c-Met (HGFR) is a membrane receptor that is essential for embryonic development and wound healing. Otherwise, HGF is the only known ligand of the c-Met receptor. Upon HGF stimulation, c-Met…
Cediranib is a tyrosine kinase inhibitor that has shown promise in the treatment of cancer. It works by inhibiting the kinase activity of both C-Raf and B-Raf, leading to downregulation…